Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01146990 · ClinicalTrials.gov registry record
A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth
A clinical trial, sponsored by AMAG Pharmaceuticals.
- Completed
- Registry status
- 245
- Enrollment target
NCT01146990: Completed study, sponsored by AMAG Pharmaceuticals.
NCT01146990 is a clinical trial that has completed, run by AMAG Pharmaceuticals. The registered enrollment target is 245 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01146990 has completed, sponsored by AMAG Pharmaceuticals.
- COMPLETED
- Registry status
- 245 participants
- Enrollment target
Study Summary
In the continuing efforts to understand the benefits and risks of in utero exposure to 17P this study is designed to evaluate differences in developmental outcomes of children, aged 23 to 25 months, born to mothers who participated in the 17P Efficacy Trial sponsored by Hologic (Protocol number 17P-ES-003).
Primary Outcome
The primary objective of this study is to determine whether there is a difference in developmental status between children, aged 23 to 25 months after adjustment for gestational age, whose mothers received 17P and those who received vehicle in the 17P Efficacy Trial.
Interventions
- DRUG ASQ-3, Bayley III, Neurologic exam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2010-11-09 |
| Est. Completion | 2020-08-13 |
What the finished NCT01146990 record still lists
NCT01146990 is an observational study that tracks outcomes without assigning an intervention. The registered 245 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which ASQ-3, Bayley III, Neurologic exam is the first listed.
NCT01146990 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01146990 about?
NCT01146990 is a clinical study titled "A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth". In the continuing efforts to understand the benefits and risks of in utero exposure to 17P this study is designed to evaluate differences in developmental outcomes of children, aged 23 to 25 months, born to mothers who participated in the 17P Efficacy Trial sponsored by Hologic (Protocol number 17P-...
What is the current status of trial NCT01146990?
This trial is currently completed. The enrollment target is 245 participants. The study started on 2010-11-09. Estimated completion is 2020-08-13.
What interventions are being tested in trial NCT01146990?
The interventions under investigation include: ASQ-3, Bayley III, Neurologic exam (DRUG).
Who is sponsoring clinical trial NCT01146990?
This trial is sponsored by AMAG Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03645928 · 245 participants · Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT04718168 · 245 participants · NA
GORE® ENFORM Biomaterial Product Study
- NCT05145127 · 245 participants · Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- NCT05446259 · 245 participants
Degenerative Cervical Myelopathy Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI